Visceral Adiposity Index as an Indicator of Cardiometabolic Risk in Patients with Congenital Adrenal Hyperplasia
- 1 February 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Metabolic Syndrome and Related Disorders
- Vol. 21 (1), 35-40
- https://doi.org/10.1089/met.2022.0060
Abstract
Aim: To evaluate the cardiometabolic risk in patients with CAH (21 (OH) enzyme deficiency) on the basis of the visceral adiposity index (VAI), which indicates dysfunction of the visceral adipose tissue (VAT). Materials and Methods: A total of 41 patients and 38 body mass index (BMI), age, and gender-matched healthy controls (HC) were included. The patients' and HCs' age, gender, waist circumference (WC), BMI information and total cholesterol (TC), high-density lipoprotein (HDL), triglyceride (TG) values, smoking, and medication history were obtained from medical charts. Weight, height, WC, and blood pressure levels were measured. Patients' and HCs' BMI, Framingham risk scores (FRS), VAI and Ferriman–Gallwey scores were calculated. The patients' and HCs' age, gender TC, HDL, and TG, androstenedione, dehydroepiandrosterone sulfate (DHEASO4), 17 hydroxyprogesterone (17(OH)P) values, smoking, and medication history were obtained from medical charts. Body fat and muscle mass levels were measured with Tanita T 6360. Results: Gender distribution, mean age, and BMI of patients with CAH were 34/7, 30 ± 8, 27 ± 5.4; HC subjects 30/8, 30 ± 6, 27 ± 3.8 (P = 0.9, 0.6, 0.9, respectively). The VAI values of patients with a diagnosis of CAH 3.7 (2.3–6.9) were found to be significantly higher than those of HC patients 2.5 (1.8–3.9; P = 0.02). The mean glucocorticoid doses of the patients were 17 ± 9 mg/day. The glucocorticoid dose level was determined as independent risk factor on the FRS (P = 0.03, β = 0.04) and VAI (P = 0.018, β = 0.17). Conclusion: Glucocorticoid dose optimization should be done more carefully to improve metabolic and cardiovascular outcomes in CAH patients.Keywords
This publication has 19 references indexed in Scilit:
- Visceral adiposity index as a useful tool for the assessment of cardiometabolic disease risk in women aged 65 to 74Diabetes/Metabolism Research and Reviews, 2018
- Congenital adrenal hyperplasiaThe Lancet, 2017
- Visceral adiposity index and 10-year cardiovascular disease incidence: The ATTICA studyNutrition, Metabolism and Cardiovascular Diseases, 2017
- Cardiovascular risk factors and events in women with androgen excessJournal of Endocrinological Investigation, 2014
- Relationship Between Final Height and Health Outcomes in Adults With Congenital Adrenal Hyperplasia: United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE)Journal of Clinical Endocrinology & Metabolism, 2014
- The framingham risk score, diet, and inflammatory markers in Korean men with metabolic syndromeNutrition Research and Practice, 2012
- Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2010
- Visceral Adiposity IndexDiabetes Care, 2010
- Cardiovascular Disease Risk in Adult Women with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase DeficiencySeminars in Reproductive Medicine, 2009
- Use and Abuse of HOMA ModelingDiabetes Care, 2004